All In Biotech

Free tool

FAERS Monitor: Reblozyl

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761136 or its brand name (Reblozyl, Luspatercept-Aamt). Reports on generic versions are filed under their own applications.

Reports

2,614

Serious

1,604

61% of reports

Hospitalization

568

Death reported

414

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death244
  • off label use193
  • haemoglobin decreased144
  • fatigue137
  • drug ineffective114
  • weight decreased92
  • product storage error85
  • dizziness84
  • myelodysplastic syndrome75
  • dyspnoea73
  • fall70
  • asthenia57
  • weight increased56
  • pneumonia55
  • diarrhoea51

Reports by year received

View as table
YearReports
20182
20193
2020142
2021248
2022440
2023325
2024494
2025536
2026424

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,545 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
myelodysplastic syndromeSignal7541.933.52,943
haemoglobin decreasedSignal14411.39.61,346
product storage errorSignal857.86.3500
weight decreasedSignal922.72.294
deathSignal2442.32.0181
weight increasedSignal562.01.628
off label use1931.81.567
fall701.71.319
fatigue1371.41.217
pneumonia551.41.15
dizziness841.41.18
asthenia571.20.92
dyspnoea731.00.80
drug ineffective1140.70.616
diarrhoea510.60.511

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.